Taisho Pharmaceutical Co., Ltd.

Mercian Corporation

Sadafumi Omura

Shigeo Morimoto

Takashi Adachi

Kazunori Hanada

Kazutoshi Mizoue

Michio Yamagishi

Masaharu Tamai

Kiyoshi Oguma

Taku Mizutani

Haruo Seto

Noboru Otake

Yoshiaki Watanabe

Joji Sasaki

Akira Kawashima

Hiroshi Hara

Jiro Sawada

Yoko Takahashi

Takatoshi Nagate

Rokuro Okamoto

Hideyo Yamaguchi

Kazuhiko Okamura

Nobuhiko Katunuma

Koji Takeda

Kazuo Numata

Kiyoshi Kimura

Naoharu Watanabe

Michinori Shibata

Sadao Machida

Shinjuro Namiki

Kazuhiko Sugita

Tadayasu Okazaki

Kunio Kangouri

Toshiro Amamoto

Akiko Mikami

Masahuru Tamai

A method for introducing hydroxyl groups into vitamin D compound at the 1.alpha.- and/or 25-positions in the presence of a cyclodextrin compound by the use of a reaction mixture containing a microorganism being capable of hydroxylating vitamin D compound or a enzyme produced from the microorganism, is disclosed.

Method for the biological preparation of hydroxyvitamin D compounds

Mucor circinelloides f. griseo-cyanus IFO 4563 is cultivated in a medium containing 6-O-methylerythromycin A as a substrate to obtain 14-hydroxy-6-O-methyl-erythromycin A. This compound and its salt have anti-bacterial activity.

Process for preparing 14-hydroxy-6-O-methyl-erythromycin A

Tripeptide derivatives of the formula ##STR1## wherein R is a formyl group or a dimethoxymethyl group have antitumor and enzyme inhibition effects.

Novel tripetide derivatives

A method for introducing hydroxyl groups into vitamin D compounds at 1.alpha.- and/or 25-positions by use of a solution containing the mycelium of Actinomycetales being capable of hydroxylating vitamin D compound or the enzyme produced from the mycelium, is disclosed.

Method for preparing vitamin D compounds

Method for the treatment of systemic mycosis of mammals comprises administering (S)-2-amino-5-hydroxy-4-oxopentanoicacid in a therapeutically effective amount to said mammals suffering from mycosis, typically candidosis.

Method for the treatment of systemic mycosis

This invention is directed to novel peptide derivatives. Said peptide derivatives are useful as a substrate for the activity assay of enzymes of the group EC 3. 4. 22, for example, cathepsin L, cathepsin B and cathepsin H. Said peptide derivatives which contain L-methionine radical are prepared according to the methods conventional in peptide chemistry. As typical examples are mentioned D-leucyl-L-tyrosyl-L-methionine-.beta.-naphthylamide formate, .beta.-alanyl-L-tyrosyl-L-methionine-.beta.-naphthylamide formate and succinyl-L-tyrosyl-L-methionine-p-nitroanilide.

Peptide derivatives

Novel erythromycin B derivatives of the formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are each hydrogen or methyl, and the pharmaceutically acceptable acid addition salts thereof are disclosed. They exhibit excellent in vivo antibacterial activity against Gram-positive bacteria.

Erythromycin B derivatives

Novel erythromycin A derivatives of the formula ##STR1## wherein R is hydrogen or methyl, and the pharmaceutically acceptable acid addition salts thereof are disclosed. They exhibit excellent antibacterial activity against erythromycin resistant bacteria, Gram-positive bacteria and Mycoplasma species.

Erythromycin A derivatives

An epoxysuccinyl amino acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen, alkali metal, benzyl or cycloalkyl having 5 to 6 carbon atoms, R.sup.2 is alkyl having 3 to 4 carbon atoms, R.sup.3 is hydrogen, benzyloxycarbonyl, acetyl or benzoyl, and n is an integer of 2 to 7. The subject compounds exhibit inhibitory activity towards thiol protease, especially, calcium-activated neutral thiol protease which exists in excess in muscle tissues of mammals afflicted with muscular dystrophy.

Epoxysuccinyl amino acid derivatives

An epoxysuccinyl amino acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen or alkali metal, R.sup.2 is isobutyl, R.sup.3 is hydrogen or benzyloxycarbonyl, and n is an integer of 5 to 7. The subject compounds exhibit inhibitory activity towards thiol protease, especially, calcium-activated neutral thiol protease which exists in excess in muscle tissues of mammals afflicted with muscular dystrophy.

The epoxysuccinic acid derivatives of this invention are prepared by esterification of an epoxysuccinic acid or a halide thereof, by partial hydrolysis of an epoxysuccinic acid diester, by amidation of an epoxysuccinic acid monoester, or by hydrolysis of an epoxysuccinic acid amide monoester. These epoxysuccinic acid derivatives have excellent thiol protease inhibitory activity and anti-inflammatory activity without the acceleration of vascular permeability.

Epoxysuccinic acid derivatives

An epoxysuccinic acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen, alkali metal, alkyl having 1-2 carbon atoms, cycloalkyl having 5-6 carbon atoms or benzyl, R.sup.2 is alkyl having 3-4 carbon atoms or benzyl, R.sup.3 is hydrogen or methyl, and R.sup.4 is alkyl having 1-10 carbon atoms, phenyl, benzyl, phenethyl, cycloalkyl having 3-6 carbon atoms or a group of the formula ##STR2## wherein R.sup.5 is hydrogen, alkyl having 1-4 carbon atoms or said alkyl substituted with hydroxy, methylmercapto, phenyl, hydroxyphenyl, indolyl, an optionally protected carboxy, an optionally protected amino or an optionally protected guanidino, and R.sup.6 is hydroxy, alkalimetaloxy, alkoxy having 1-2 carbon atoms, benzyloxy, amino or dimethylamino, or R.sup.3 and R.sup.4 taken together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring, or said heterocyclic ring substituted with a protected carboxy.

A novel compound of the formula ##STR1## and the salts thereof, derived from dianemycin, are useful as antiprotozoal and antibacterial agents.

Novel dianemycin derivative

The novel antibiotics represented by the formula ##STR1## wherein either (a) R.sup.1 is hydroxy and R.sup.2 is hydrogen, or (b) R.sup.1 is methoxy and R.sup.2 is hydroxy, and the salt thereof, are produced by the cultivation of the organism Streptomyces hygroscopicus TM-531 under aerobic conditions. They are separated from coproduced Antibiotic TM-531 as disclosed in U.S. Pat. No. 4,269,971 and from each other by chromatography on silica gel.

Antibiotics TM-531 B and TM-531 C

An epoxysuccinic acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen, alkali metal, alkyl having 1-2 carbon atoms, cycloalkyl having 5-6 carbon atoms or benzyl, R.sup.2 is alkyl having 3-4 carbon atoms or benzyl, R.sup.3 is hydrogen or methyl, and R.sup.4 is alkyl having 1-10 carbon atoms, phenyl, benzyl, phenethyl or cycloalkyl having 3-6 carbon atoms or R.sup.3 and R.sup.4 taken together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring, or said heterocyclic ring substituted with a protected carboxy.

Growing community of inventors

Ageo, Japan

Sadafumi Omura